BNET Industries
Market Cap:$174.8K
Last Fiscal Year Sales:$49.7K
- Public
- US
Dow Jones Description
We are an early-stage company established for the purpose of commercializing, marketing and selling over-the-counter, or OTC, pharmaceutical products that we believe incorporate topical and transdermal formulation platforms. We began our operations in January 2001, as a division of BioChemics, a biopharmaceutical company engaged in the development of transdermal and topical drug delivery systems. BioChemics is based in Danvers, Massachusetts. BioChemics was founded in 1989 by John J. Masiz and was incorporated in Delaware in 1991. By virtue of his ownership of BioChemics and Vaso Active, Mr. Masiz controls both BioChemics and Vaso Active. BioChemics began developing the VALE technology in 1989 and has subsequently been issued 4 U.S. patents in connection with this technology. We are also based in Danvers, Massachusetts. In January 2003, we incorporated in Delaware and became an independent subsidiary of BioChemics, focused on the further commercialization of our existing OTC products and the development of new OTC product candidates.
Acting President & CEO
Joseph FrattaroliNumber of Employees 5
Contact Information
99 Rosewood Dr Ste 260
Danvers, Massachusetts 01923
(978) 750-1991
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
News & Analysis
Filter by
vaso active pharmaceuticals inc. - All News and Analysis
Milberg Weiss Announces the Filing of a Class Action Suit against Vaso Active Pharmaceuticals, Inc. and Certain of Its Officers and Directors on Behalf of Investors
Business Editors/Legal Writers NEW YORK--BUSINESS WIRE--May 12, 2004 The law firm of Milberg Weiss Bershad & Schulman LLP announces that a class action lawsuit was filed on April 15, 2004, on behalf of purchasers of the securities of Vaso Active Pharmaceutical, Inc. ("Vaso" or the "Company") (OTC: VAPH.PK)...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Joseph Frattaroli | Acting President & CEO |
| Stephen G. Carter | Vice President & Chief Scientific Officer |
| Stephen Cataldo | Director, Marketing |
| Elizabeth Russo | Controller |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Robert E. Anderson | Chair of Board |
| Brian J. Strasnick | Board of Directors |
| Bruce A. Shear | Board of Directors |
| D'Anne Hurd | Board of Directors |
| Ronald Guerriero | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Vaso Active Pharmaceuticals, Inc. | Acting President & CEO | Current |
| Organization | Position | Status |
|---|---|---|
| Vaso Active Pharmaceuticals, Inc. | Vice President & Chief Scientific Officer | Current |
| Vaso Active Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Vaso Active Pharmaceuticals, Inc. | Director, Marketing | Current |
| Organization | Position | Status |
|---|---|---|
| Vaso Active Pharmaceuticals, Inc. | Controller | Current |
| Organization | Position | Status |
|---|---|---|
| Vaso Active Pharmaceuticals, Inc. | Chair of Board | Current |
| Organization | Position | Status |
|---|---|---|
| Vaso Active Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Vaso Active Pharmaceuticals, Inc. | Board of Directors | Current |
Ms. D Anne Hurd has been a Director of the Company since October 2006. Ms. Hurd currently serves as Vice President and General Counsel for Worcester Polytechnic Institute (WPI) and Vice President for Business Development at Gateway Park (WPI s life sciences/ bioengineering development). She has held these positions since January 2006. Ms. Hurd is Chairman of the Audit Committee of Data Translation, Inc. (DATX) and Vaso Active Pharmaceuticals, Inc. (VAPH). She brings over 30 years of experience in start-ups as well as established public companies, most recently serving as Senior Vice President, CFO and Treasurer of NMS Communications, Inc. (NMSS). Ms. Hurd served as CFO and General Counsel of STARBAK Communications, Inc. and its predecessor company, Vividon, Inc. from March 2001 until January 2004. Prior to joining Vividon, Inc., Ms. Hurd served as CFO and General Counsel for NaviPath, Inc., a majority-owned subsidiary of CMGI, Inc. Previously, Ms. Hurd was the CFO and General Counsel for SmartRoute Systems, Inc., the Cambridge, MA provider of real-time, digital traffic data. Ms. Hurd s years of experience in executive-level management also includes senior finance positions at GTE Corporation and PepsiCo, Inc. where she was responsible for their global cash management and banking relationships, and seven years as an associate with the Boston law firm Burns & Levinson, where she advised private and public clients on all aspects of corporate finance and securities law. Ms. Hurd also serves on the Board of Directors of the New England Chapter of the National Association of Corporate Directors (NACD) as well as several other nonprofit entities. During the Company s fiscal year ended March 31, 2008 ( Fiscal 2008 ), the Board of Directors held eight meetings and acted twice by unanimous written consent. During Fiscal 2008, each director attended each meeting. All of the Board members attended the Company s 2007 Annual Meeting of Stockholders either in person or telephonically, and the Company expects that all of the Board members will attend the 2008 Annual Meeting.
| Organization | Position | Status |
|---|---|---|
| Gateway Park LLC | Vice President for Business Development | Current |
| National Association of Corporate Directors | Board of Directors | Current |
| Micronetics Inc. | Board of Directors | Current |
| Vaso Active Pharmaceuticals, Inc. | Board of Directors | Current |
| Smartroute Systems, Inc. | Cfo | Former |
| Smartroute Systems, Inc. | General Counsel | Former |
| Vividon | Former |
| Organization | Position | Status |
|---|---|---|
| Vaso Active Pharmaceuticals, Inc. | Board of Directors | Current |
Industry Transcripts by Seeking Alpha
-
Neogen Corporation F2Q10 (Qtr End11/30/09) Earnings Call Transcript
on Dec 18, 2009about NEOG
-
Schiff Nutrition International, Inc. F2Q10 (Qtr End 11/30/09) Earnings Call Transcript
on Dec 17, 2009about WNI
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes

